This guideline covers diagnosis and surgical and pharmacological treatment of women and men with early and locally advanced breast cancer. It aims to improve early identification and treatment of breast cancer to prevent disease progression and reduce deaths.
This guideline includes recommendations on:
- referral, diagnosis and preoperative assessment of women with early and locally advanced breast cancer
- treatment with surgery to the breast and axilla
- breast reconstruction
- adjuvant treatment with endocrine therapy, chemotherapy, biological therapy and radiotherapy
- primary systemic therapy
- complications of local treatment and menopausal symptoms
Who is it for?
- Healthcare professionals
- People with early and locally advanced breast cancer and their families and carers
Is this guideline up to date?
Guideline development process
This guideline updates and replaces NICE guidance TA107 (August 2006), TA108 (September 2006) and TA109 (September 2006).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.